Current Epidemiological Data Can Help Predict Future Incidence of CCA

March 2023, Vol 4, No 1

Cholangiocarcinoma (CCA), a rare and aggressive form of cancer, has seen a steady increase in incidence in the United States, with a predominant increase in intrahepatic CCA (iCCA), from 2001 to 2017 based on a recent epidemiological study. Dr Sri Harsha Tella presented results from a retrospective study that aimed to evaluate the future incidence of CCA with subgroup stratification based on CCA subtype, age, sex, and race in the hope that epidemiological data may aid in prevention planning and treatment strategies.

Histologically confirmed patient cases of CCA from 2000 to 2017 were obtained from 18 of the National Cancer Institute’s Surveillance, Epidemiology, and End Results registries. Age-period-cohort models were applied to estimate future CCA incidence rates (per 100,000). Incidence forecast multiplied by corresponding US census population projections was used to estimate disease burden. A total of 12,737 patients with iCCA and 8395 with extrahepatic CCA (eCCA) were included in the final analysis. The overall observed age-adjusted incidence of iCCA from 2000 to 2017 was 1.07 and is predicted to rise by 99% to 2.13 by 2029, with predominant increases in patients aged 70 to 79 years and in White men and women. The incidence of eCCA is also expected to rise 36.5% compared with 2001 to 2017, from 0.74 to 1.01, by 2029, predominantly in Black and Hispanic patients. Notably, a stable and decreasing incidence rate was seen in White and Asian women.

Overall, it is expected that the incidence of iCCA and eCCA will rise over the coming years. These studies suggest the need for urgent preventive measures; however, further studies are needed to determine contributing factors to the increase in CCA incidence.

Source: Tella SH, Hodge DO, Wieczorek MA, et al. A glimpse into the future of cholangiocarcinoma: predicting the future incidence based on the current epidemiological data. Poster presented at: ASCO Gastrointestinal Cancers Symposium, January 19-21, 2023; San Francisco, CA. Abstract 616.

Related Items

Tasurgratinib for Patients With FGFR2 Gene Fusion–Positive CCA: A Phase 2 Study
March 2024, Vol 5, No 1
Junji Furuse, MD, PhD, presented the results of a phase 2 study of tasurgratinib efficacy on patients with FGFR2 fusion-positive cholangiocarcinoma following gene fusion status confirmation by fluorescence in situ hybridization.
Safety and Efficacy of Telotristat Ethyl Plus First-Line Chemotherapy in Patients With Advanced BTC: A Phase 2, Open-Label Study
March 2024, Vol 5, No 1
Richard Kim, MD, presented the results of a phase 2, open-label study of patients who underwent telotristat ethyl plus first-line chemotherapy for the treatment of advanced biliary tract cancer.
Efficacy and Safety of Brigimadlin (BI 907828) in Patients With Advanced BTC: Data From 2 Phase 1a/1b Dose-Escalation/Expansion Trials
March 2024, Vol 5, No 1
Teresa Macarulla, MD, PhD, presented the results of 2 phase 1a/1b dose-escalation/expansion trials, studies that measured the efficacy and safety of brigimadlin in patients with advanced biliary tract cancer.
COMPANION-002: A Phase 2/3 Randomized Study Design of CTX-009 Combination in Second-Line BTC
March 2024, Vol 5, No 1
A recombinant bispecific antibody, CTX-009, is discussed regarding its role in an ongoing phase 2/3 open-label, randomized, controlled study—a study being conducted to measure the efficacy of CTX-009 in previously treated, advanced, or metastatic biliary tract cancer.
A Phase 2 Clinical Trial of Anlotinib Plus TQB2450 (PD-L1 Blockade) Plus Nab-Paclitaxel and Cisplatin as First-Line Treatment for Advanced BTC
March 2024, Vol 5, No 1
Cholangiocarcinoma experts presented the preliminary results of a phase 2 clinical trial regarding anlotinib plus TQB2450, nab-paclitaxel, and cisplatin—a study conducted for the treatment of advanced biliary tract cancer.
Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC
March 2024, Vol 5, No 1
Zongli Zhang, MD, PhD, presented the preliminary results of an ongoing single-arm, multicenter, open-label, real-world study analyzing the efficacy and safety of surufatinib as a second-line treatment option for patients with biliary tract cancer.
Genomic Factors Indicating Sensitivity to IO and Chemotherapy in CCA
March 2024, Vol 5, No 1
Riya Jayesh Patel, MD, presented how the impact of transcriptomic signatures related to chemotherapy and immunotherapy sensitivity in the cholangiocarcinoma (CCA) cohort of The Cancer Genome Atlas could serve as evidence supporting the effectiveness of metabolism-targeted therapies in overcoming CCA therapeutic resistance.
Examining Real-World Testing, Treatment Patterns, and Outcomes After Liquid Biopsy in aCCA
March 2024, Vol 5, No 1
Amit Mahipal, MD, presented results from a real-world data study examining the rates of molecular alterations detected using circulating tumor DNA (ctDNA) for patients receiving ivosidenib following circulating tumor ctDNA-detected IDH1 mutations.
A Phase 2 Primary Analysis of Tislelizumab Plus Lenvatinib and GEMOX as Conversion Therapy in Potentially Resectable Locally Advanced BTC (ZSAB-TransGOLP)
March 2024, Vol 5, No 1
Jia Fan, PhD, presented results from a phase 2 trial that investigated the efficacy and safety of lenvatinib and a programmed cell death protein-1 antibody as conversion therapy for the treatment of potentially resectable and locally advanced biliary tract cancer.
Role of CD27 Agonist in Combination With PD-L1 and MEK Inhibition on Antitumor Effect and CD8+ T Cells: Expanding Immunotherapy Options in CCA
March 2024, Vol 5, No 1
Frances J. Bennett, MD, presented the results of a phase 2 trial that tested the antitumor effect of dual programmed death-ligand 1 plus mitogen-activated protein kinase inhibition in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: